Al-Ziftawi, N.H.; Alam, M.F.; Elazzazy, S.; Shafie, A.A.; Hamad, A.; Mohamed Ibrahim, M.I.
Cost-Effectiveness and Cost-Utility of Palbociclib versus Ribociclib in Women with Stage IV Breast Cancer: A Real-World Data Evaluation. Int. J. Environ. Res. Public Health 2023, 20, 512.
https://doi.org/10.3390/ijerph20010512
AMA Style
Al-Ziftawi NH, Alam MF, Elazzazy S, Shafie AA, Hamad A, Mohamed Ibrahim MI.
Cost-Effectiveness and Cost-Utility of Palbociclib versus Ribociclib in Women with Stage IV Breast Cancer: A Real-World Data Evaluation. International Journal of Environmental Research and Public Health. 2023; 20(1):512.
https://doi.org/10.3390/ijerph20010512
Chicago/Turabian Style
Al-Ziftawi, Nour Hisham, Mohammed Fasihul Alam, Shereen Elazzazy, Asrul Akmal Shafie, Anas Hamad, and Mohamed Izham Mohamed Ibrahim.
2023. "Cost-Effectiveness and Cost-Utility of Palbociclib versus Ribociclib in Women with Stage IV Breast Cancer: A Real-World Data Evaluation" International Journal of Environmental Research and Public Health 20, no. 1: 512.
https://doi.org/10.3390/ijerph20010512
APA Style
Al-Ziftawi, N. H., Alam, M. F., Elazzazy, S., Shafie, A. A., Hamad, A., & Mohamed Ibrahim, M. I.
(2023). Cost-Effectiveness and Cost-Utility of Palbociclib versus Ribociclib in Women with Stage IV Breast Cancer: A Real-World Data Evaluation. International Journal of Environmental Research and Public Health, 20(1), 512.
https://doi.org/10.3390/ijerph20010512
